Enveric Biosciences Announces Registration of Five Trademarks

Rhea-AI Impact

(Very High)

Rhea-AI Sentiment

(Positive)

Key Terms

intellectual property regulatory

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

ind filing regulatory

An IND filing is a formal application submitted to a drug regulator asking permission to begin testing a new medicine or biological therapy in people. Think of it like obtaining a building permit before construction begins: it signals that preclinical safety data were enough for regulators to allow human trials, making it a key milestone that can reduce uncertainty, unlock funding or deals, and increase a biotech company's near-term value—while still leaving clinical risk.

house marks technical

House marks are the internal price estimates or valuations a brokerage, trading desk, or research team assigns to securities and positions for pricing, risk control, and trading decisions. They matter to investors because these private estimates help determine how a firm quotes trades, sets guidance and margin, and reports performance—like a shop’s private price tag that guides staff actions but can differ from public market quotes or independent appraisals.

03/18/2026 - 08:00 AM

Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company’s trademarks, including its house marks, Enveric and Enveric Biosciences.

“The registration of a Company’s house marks, such as our marks Enveric and Enveric Biosciences, is an important intellectual property milestone supporting our branding strategies for our future products. We thank the Canadian Intellectual Property Office for its recent action,” said Joseph Tucker, PhD, CEO of Enveric.

In addition, the Canadian Intellectual Property Office registered two “Plus Marks” which are designs used on Enveric product packaging, and its trademark, “Next Generation Mental Health.” Dr. Tucker continued, “These additional marks reflect the Company’s view of the expected positive impact of its pipeline products under development on mental health, including the lead molecule EB-003, for which an IND filing with the FDA is planned in 2026.”

Dr. Tucker concluded: “Registration of the house marks, Enveric and Enveric Biosciences, in the United States and now in Canada, along with existing registrations of the mark, Enveric, in Europe and the U.K. helps secure our branding strategy in these important future markets of interest for EB-003.”

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂_A and 5-HT₁_B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.